EVENTS | VIEW CALENDAR
Sigmoid Pharma announces acquisition of Freund Pharmatec
DUBLIN—In early February, Sigmoid Pharma Ltd., a privately owned, specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases using its proprietary SmPill solid oral delivery system, announced that it has entered into an agreement to acquire Freund Pharmatec Ltd.
Freund Pharmatec, a wholly owned Irish subsidiary of Freund Corp., is a specialist drug delivery technology company focused on proprietary mini-encapsulation and layering technologies.
Through this acquisition, Sigmoid will acquire 100-percent ownership of the Freund Pharmatec entity and assets, including a state-of-the-art GMP pharmaceutical manufacturing facility and research laboratories. Sigmoid expects to benefit from the expanded manufacturing capacity that the existing Freund Spherex and Granulex technologies provide, as well as various intellectual property assets.
Freund Pharmatec will continue ongoing customer-funded research and development programs under Sigmoid management, and will support manufacturing for Sigmoid’s clinical development pipeline, including its late-stage CyCol program, which is in development for ulcerative colitis. “Sigmoid and Freund have had a longstanding relationship with a shared focus on utilizing seamless minicapsule technology,” said Dr. Ivan Coulter, CEO and founder of Sigmoid Pharma. “This acquisition comes at an exciting time in Sigmoid’s development and will enable us to advance our lead programs through late-stage clinical development and expedite our goal of becoming a global leader in the development of oral, effective and safe gastrointestinal disease therapeutics.”